Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00313092
Status:
TERMINATED
Last Update Posted:
2015-10-02
First Post:
2006-04-10
Brief Title:
Obstructive Sleep Apnea Syndrome in Glaucoma
Sponsor:
Selim Orguel
Organization:
University Hospital Basel Switzerland
Study Overview
Official Title:
Does Plasma Matrix-metalloproteinase Activity Predict Glaucomas in Patients With OSAS Obstructive Sleep Apnea Syndrome and Does the Level of Plasma Matrix-metalloproteinase Activity Decrease After One Month of nCPAP-treatment
Status:
TERMINATED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
recruiting problems
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with OSAS and if the level of plasma matrix-metalloproteinase activity will decrease after one month of nCPAP-treatment
Detailed Description:
Glaucoma is a leading cause of blindness world-wide Chronic primary open-angle glaucoma is the most common form among Caucasian patients The key feature of glaucoma is damage to the optic nerve head which is not necessarily related to an increased intraocular pressure The prevalence of glaucoma among the patients with sleep apnoea was 72 normal-tension glaucoma 29 primary open-angle glaucoma 43 The prevalence of obstructive sleep apnoea syndrome OSAS is around 4-10 for men and 2-4 for women Matrix metalloproteinases MMPs substrates include essentially all extracellular matrix components as well as a wide array of molecules involved in intracellular adhesion cell-matrix interaction and cell signalling However MMPs effects are not restricted to extracellular matrix degradation The prevalence of increased MMP in patients with OSAS and its predicting value for an additional glaucoma are not known Further we do not know if treatment of OSAS with nasal continuous positive air pressurenCPAP can decrease the MMP activity With this study we want to determine the prevalence of MMP activity and the prevalence of glaucoma in patients with OSAS Further we want to investigate if a nCPAP treatment period of four weeks decreases the MMP activity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None